LON:GENI

GENinCode Interim Earnings Results & Report

GENinCode logo
GBX 0.56 -0.04 (-6.67%)
As of 11/20/2026 11:39 AM Eastern

GENinCode reported Interim earnings on September 29, 2026. The company reported EPS of -GBX 0.38.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

GENinCode EPS Results

Actual EPS
-GBX 0.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GENinCode Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

GENinCode Interim Earnings FAQ

GENinCode (LON:GENI) reported earnings of -GBX 0.38 per share for Interim. The report was announced on Tuesday, September 29, 2026.

GENinCode Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More GENinCode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENinCode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENinCode and other key companies, straight to your email.

About GENinCode

GENinCode (LON:GENI) is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

View GENinCode Profile